Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $107 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and maintained a $107 price target.
April 05, 2024 | 1:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Ultragenyx Pharmaceutical and maintained a $107 price target.
The reiteration of an Overweight rating and the maintenance of a $107 price target by a reputable analyst like Kristen Kluska from Cantor Fitzgerald could signal a strong vote of confidence in Ultragenyx Pharmaceutical's stock. This endorsement may positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90